Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia.

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI:10.1038/leusup.2012.19
P Corradini, L Farina
{"title":"Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia.","authors":"P Corradini,&nbsp;L Farina","doi":"10.1038/leusup.2012.19","DOIUrl":null,"url":null,"abstract":"<p><p>Although hematopoietic stem cell transplantation (allogeneic SCT (allo-SCT)) is the treatment of choice for many aggressive hematological malignancies, the role of allo-SCT in chronic lymphocytic leukemia (CLL) is still a matter of debate and can be considered one of the more important challenges for the next decade. In the era of novel drugs and humanized antibodies, the long-term outcome of patients has improved, and a critical reappraisal of autologous and allo-SCT in CLL treatment is warranted. </p>","PeriodicalId":91571,"journal":{"name":"Leukemia supplements","volume":"1 Suppl 2","pages":"S33-4"},"PeriodicalIF":0.0000,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/leusup.2012.19","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/leusup.2012.19","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/8/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Although hematopoietic stem cell transplantation (allogeneic SCT (allo-SCT)) is the treatment of choice for many aggressive hematological malignancies, the role of allo-SCT in chronic lymphocytic leukemia (CLL) is still a matter of debate and can be considered one of the more important challenges for the next decade. In the era of novel drugs and humanized antibodies, the long-term outcome of patients has improved, and a critical reappraisal of autologous and allo-SCT in CLL treatment is warranted.

未来十年的挑战:异基因干细胞移植治疗慢性淋巴细胞白血病。
尽管造血干细胞移植(同种异体SCT)是许多侵袭性血液系统恶性肿瘤的治疗选择,但同种异体SCT在慢性淋巴细胞白血病(CLL)中的作用仍然存在争议,并可能被认为是未来十年更重要的挑战之一。在新药和人源化抗体的时代,患者的长期预后得到了改善,对CLL治疗中自体和同种异体sct的关键重新评估是有必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信